Phase I human study and preclinical evaluations of OcuRing™-K showed no treatment-related safety concerns, supporting ...
Additional proof of concept data consistent and strengthen data set shared at ASH 2025Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 SAN FRANCISCO, CALIFORNIA / ACCESS ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic ...
The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...
Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...
The two IPOs, which follow radiopharma specialist Aktis Oncology's filing last week, have investors and industry watchers ...
This clinical trial will determine whether focused ultrasound can safely and effectively treat metastatic brain tumors when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback